Research in the UAE

High Satisfaction with Cladribine Tablets in Gulf RMS Patients

Published on Sat, 12 Aug 2023

Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study

A multicentre observational study in the Arabian Gulf evaluated treatment satisfaction with cladribine tablets (CladT) in 58 relapsing multiple sclerosis (RMS) patients. Results showed high scores for overall satisfaction (77.8%), ease of use (87.4%), tolerability (94.2%), and perceived effectiveness (76.2%). Scores were consistent across demographics and disease characteristics. No relapses or serious adverse events occurred, with lymphopenia reported in 16% of patients. The study underscores CladT’s convenience and effectiveness as a patient-preferred therapy for RMS in the region.

Related research

Learn More
Switching from Fingolimod/Natalizumab to Cladribine Without Rebound
Fri, 1 Dec 2023

Switching from Fingolimod/Natalizumab to Cladribine Without Rebound

Learn More
Learn More
Adherence Challenges for High-Efficacy MS Therapies
Fri, 22 May 2020

Adherence Challenges for High-Efficacy MS Therapies

Learn More
Learn More
Living with MS: A Biopsychosocial Perspective
Tue, 17 Aug 2021

Living with MS: A Biopsychosocial Perspective